MEA CTI EMEA Managing Director Alaa Assem is a physician, ophthalmologist and MBA holder with over 30 years of experience in pharma and clinical research organisations. Since joining CTI, he has strengthened the company’s presence in the Middle East, focusing on rare disease, gene and cell therapy, oncology, and transplantation. CTI…
France As global vaccine development grows more complex and capital more selective, Valneva is sharpening its identity and returning decisively to its roots. The company’s decision to close its Nantes site and re-centralise French operations in Lyon is more than operational streamlining; it signals a strategic recommitment to one of Europe’s…
Hong Kong Hong Kong is quietly re-engineering how clinical research is organised and delivered across one of the world’s most dynamic life-sciences regions. Through the Greater Bay Area International Clinical Trial Institute (GBAICTI), Hong Kong’s long-established academic and regulatory strengths are being connected with the scale, infrastructure, and talent of the wider…
Denmark Maja Kramp, General Manager at Ferring Nordics, discusses the company’s long-standing commitment to innovation in reproductive medicine and the pivotal role of the Nordic region in Ferring’s global strategy. She highlights the region’s strong life sciences ecosystem, Denmark’s leadership in global R&D, and the company’s values of collaboration, care, and…
Australia Australia will shortly have its latest national election, and we are again seeing pharmaceuticals being front and centre in the campaign. The starter’s gun has been fired for the 2025 Australian federal election, which will be held on Saturday, 3 May, just 5 days after Canada’s forthcoming national election.…
Global Writing in the April 2025 edition of DIA’s Global Forum magazine, Christopher Morrison and Richard Xie of RA Capital Management L.P., introduce the recently published cost-effectiveness analyses methodology which incorporates key value elements and drivers that are omitted or incompletely captured in traditional clinical outcome assessments. Accelerating scientific discoveries…
USA The US pharmaceutical industry is scrambling to align with President Donald Trump’s policy agenda, but may not get all it wishes for… In its first few weeks in power, the emboldened second Trump administration has enacted a scattergun set of executive orders, covering everything from swingeing cuts to the…
Saudi Arabia Marwan Omar, General Manager of Ferring in the GCC, lays out the company’s growth strategy and its deep commitment to the region. With a focus on local talent development, strategic partnerships, and expanding its product portfolio, Ferring continues to strengthen its presence in reproductive medicine, gastroenterology, and uro-oncology. Investing…
Puerto Rico Gustavo A. Hermida, President of CIC Construction Group, shares the remarkable journey of Puerto Rico’s leading general contractor. Built on a foundation of excellence in the pharmaceutical sector, CIC has successfully diversified into healthcare, hospitality, and housing while upholding its rigorous standards of safety, quality, and timely delivery. Hermida highlights…
USA As Breast Cancer Awareness Month 2024 draws to a close, PhRMA’s Elizabeth Carpenter lays out the massive progress made in breast cancer treatment outcomes over the past half-century. However, Carpenter warns that further progress in breast cancer R&D is under threat, highlighting three key policy barriers that must be removed…
Switzerland Jürg Utzinger, Director of the Swiss Tropical and Public Health Institute (Swiss TPH), addresses global health challenges, the significance of partnerships and the impact of new technologies on health outcomes. He states, “Our mission is to make the world a healthier place, focusing on topics such as climate change, infectious…
USA As healthcare costs are set to be a key issue for voters in the upcoming US presidential election, PhRMA’s Robert Zirkelbach lays out why policymakers must abandon partisan solutions that do not address underlying access and affordability issues. Instead, Zirkelbach urges for greater protection of the USA’s world-leading biopharmaceutical R&D…
See our Cookie Privacy Policy Here
